ライフサイエンスコーパス: insulin-like growth factor I

1 duplicated by administration of recombinant insulin-like growth factor I.

2 K1 is phosphorylated on Thr60 in response to insulin-like growth factor I.

3 ed by cancer cells was capable of binding to insulin-like growth factor I.

4 by platelet-derived growth factor (PDGF) and insulin-like growth factor I.

5 triggered by interleukin 6 (IL-6) but not by insulin-like growth factor-I.

6 se to mechanical loading and to the anabolic insulin-like growth factor-I.

7 owth factor-I mRNA but did not affect plasma insulin-like growth factor-I.

8 on of Leu(A16) among vertebrate insulins and insulin-like growth factors is a side consequence of ind

9 re local effects on growth) that occurs with insulin-like growth factor I administration, the use of

10 ation induced by low levels of Shh; however, insulin-like growth factor I alone is insufficient to in

11 Insulin-like growth factor-I also activated reconstitute

12 Insulin-like growth factor I and FBS activate NADPH oxid

13 Although changes in the metabolism of insulin-like growth factor I and glucocorticoids have be

14 Insulin-like growth factor I and IGFBP-III were correlat

15 siderable evidence that reduced secretion of insulin-like growth factor I and insulin are among the m

16 d tumor necrosis factor receptor 1 and lower insulin-like growth factor I and leptin.

17 icosterone output, but only CR reduced serum insulin-like growth factor I and leptin.

18 as stimulated in a dose-dependent fashion by insulin-like growth factor I and platelet-derived growth

19 we investigate the mechanisms through which insulin-like growth factor I and serum (FBS) activate NA

20 in circulating levels of growth hormone and insulin-like growth factor I and were, at least partiall

21 , suggesting a feedback relationship between insulin-like growth factor-I and GH in the brain.

22 ient mice were marantic and had low insulin, insulin-like growth factor-I and membrane-bound stem cel

23 Recently, we have shown that insulin-like growth factor-I and serum-derived growth fa

24 Insulin and insulin-like growth factors I and II are closely related

25 erum such as platelet-derived growth factor, insulin-like growth factor I, and insulin do not stimula

26 de the impact on serum testosterone, leptin, insulin-like growth factor I, and interleukin-6 levels.

27 erum IL-6, tumor necrosis factor receptor 1, insulin-like growth factor I, and leptin.

28 ted in media that contained thyroid hormone, insulin-like growth factor I, and LH, 40% of the putativ

29 drug-related down-regulation of VEGF, IL-6, insulin-like growth factor-I, Angiopoietin 1 (Ang1), and

30 finding is physiologically relevant because insulin-like growth factor I appears to mediate ubiquiti

31 Insulin and insulin-like growth factor-I are key growth factors, als

32 hiregulin expression, and the growth hormone/insulin-like growth factor I axis in pregnancy-induced a

33 e systems have been proposed-insulin and the insulin-like growth factor-I axis, sex steroids, and adi

34 Commercial preparations of recombinant human insulin-like growth factor I became available in 2005.

35 and, but it caused partial resistance to the insulin-like growth factor I because of a significant re

36 dlers and seems to have a specific effect on insulin-like growth factor I concentrations and growth.

37 ED decreased serum insulin-like growth factor I concentrations and increase

38 Insulin-like growth factor I concentrations seemed to be

39 ical concentrate and green tea reduced serum insulin-like growth factor-I concentrations in both male

40 intermediate for epidermal growth factor- or insulin-like growth factor I-countered apoptosis, consis

41 potential mediators include testosterone and insulin-like growth factor I deficiency, excess myostati

42 cancer cell proliferation: interleukin-6 and insulin-like growth factor I demonstrate additive and sy

43 ctile protein expression in human VSMC in an insulin-like growth factor I-dependent manner, by reliev

44 IRS-2 is active to mediate insulin-like growth factor I-dependent signals in hypoxi

45 tly and indirectly through the inhibition of insulin-like growth factor I expression.

46 , PDGF-BB, transforming growth factor-beta1, insulin-like growth factor-I, fibroblast growth factor-b

47 Treatment with insulin-like growth factor I for unequivocal growth horm

48 ntractive ocular tissues and, in response to insulin-like growth factor I, generate tractional forces

49 However, insulin, insulin-like growth factor-I, growth hormone, vascular e

50 rmonal factors that cause defects in insulin/insulin-like growth factor I (IFG-I) intracellular signa

51 n complex ways in osteoblasts, converging on insulin like growth factor I (IGF-I) expression.

52 n decreases the levels of plasma glucose and insulin-like growth factor I (IGF-1) and postpones or at

53 tic genes that are induced by Wnt-1, notably insulin-like growth factor I (IGF-I) and IGF-II.

54 n association between higher blood levels of insulin-like growth factor I (IGF-I) and increased risk

55 Insulin-like growth factor I (IGF-I) and insulin, but no

56 t colorectal cancer is positively related to insulin-like growth factor I (IGF-I) and inversely relat

57 certain the effect of high protein intake on insulin-like growth factor I (IGF-I) and markers of bone

58 Oxidative folding of insulin-like growth factor I (IGF-I) and single-chain in

59 Plasma insulin-like growth factor I (IGF-I) and the concentrati

60 k is associated with higher plasma levels of insulin-like growth factor I (IGF-I) and/or lower levels

61 Erythropoietin (EPO) and insulin-like growth factor I (IGF-I) are cytokines that

62 Insulin and insulin-like growth factor I (IGF-I) are ubiquitous horm

63 Insulin-like growth factor I (IGF-I) can promote the dif

64 g adiponectin, leptin, ghrelin, insulin, and insulin-like growth factor I (IGF-I) concentrations were

65 Increased circulating insulin-like growth factor I (IGF-I) concentrations, fre

66 f breast cancer cell motility in response to insulin-like growth factor I (IGF-I) correlates with low

67 Insulin-like growth factor I (IGF-I) exerts multiple eff

68 Growth hormone (GH) regulates insulin-like growth factor I (IGF-I) expression, and IGF

69 -p53 complexes regulate transcription of the insulin-like growth factor I (IGF-I) gene by binding to

70 Because insulin-like growth factor I (IGF-I) has been shown to e

71 We recently found that clenbuterol induces insulin-like growth factor I (IGF-I) in cardiac myocytes

72 d that supraphysiologic levels of insulin or insulin-like growth factor I (IGF-I) in combination with

73 promotion mostly attributed to generation of insulin-like growth factor I (IGF-I) in liver or at loca

74 The role of systemic and local insulin-like growth factor I (IGF-I) in the development

75 e dramatic improvement in the NMR spectra of insulin-like growth factor I (IGF-I) in the presence of

76 Insulin-like growth factor I (IGF-I) is a mitogen for va

77 Insulin-like growth factor I (IGF-I) is a pleiotropic gr

78 Insulin-like growth factor I (IGF-I) is one of several g

79 Insulin/insulin-like growth factor I (IGF-I) is unique among gro

80 Serum insulin-like growth factor I (IGF-I) levels consistently

81 ons have emphasized the favorable effects of insulin-like growth factor I (IGF-I) on left ventricular

82 s by increasing endogenous concentrations of insulin-like growth factor I (IGF-I) or the bioavailabil

83 Insulin-like growth factor I (IGF-I) plays an important

84 Laboratory studies suggest that insulin-like growth factor I (IGF-I) promotes prostatic

85 Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates

86 Among these, insulin and insulin-like growth factor I (IGF-I) regulate the develo

87 hown to regulate cell autonomous insulin and insulin-like growth factor I (IGF-I) sensitivity by tran

88 Insulin and insulin-like growth factor I (IGF-I) signal through the

89 Disruption of insulin-like growth factor I (IGF-I) signaling is a key

90 AD in mice responds positively to decreased insulin-like growth factor I (IGF-I) signaling, a pathwa

91 Insulin-like growth factor I (IGF-I) stimulates smooth m

92 In this paper, we show that delivery of insulin-like growth factor I (IGF-I) to adult skeletal m

93 The ability of insulin-like growth factor I (IGF-I) to stimulate cartil

94 In osteoblasts C/EBPbeta can increase insulin-like growth factor I (IGF-I) transcription follo

95 are improved by an N-terminal tripeptide of insulin-like growth factor I (IGF-I) treatment.

96 rylation and cleavage, which is prevented by insulin-like growth factor I (IGF-I) treatment.

97 rexpression on cellular invasiveness towards insulin-like growth factor I (IGF-I), a peptide of criti

98 these associations were related to insulin, insulin-like growth factor I (IGF-I), and leptin.

99 erous factors, including prolactin (PRL) and insulin-like growth factor I (IGF-I), both of which have

100 We delivered insulin-like growth factor I (IGF-I), fibroblast growth

101 s, including hepatocyte growth factor (HGF), insulin-like growth factor I (IGF-I), insulin-like growt

102 al muscle results in increased expression of insulin-like growth factor I (IGF-I), which is thought t

103 Here, we show that AIB1 is rate-limiting for insulin-like growth factor I (IGF-I)-dependent phenotypi

104 tenance of ICC requires insulin-dependent or insulin-like growth factor I (IGF-I)-dependent productio

105 The insulin-like growth factor I (IGF-I)-mediated MAPK casca

106 stimulating insulin receptor or by affecting insulin-like growth factor I (IGF-I)-mediated mitogenesi

107 of the alphaVbeta3 integrin is required for insulin-like growth factor I (IGF-I)-stimulated cell mig

108 reduces many circulating proteins, including insulin-like growth factor I (IGF-I).

109 causes cells to produce VEGF in response to insulin-like growth factor I (IGF-I).

110 tly reduced levels of the prosurvival factor insulin-like growth factor I (IGF-I).

111 ants, and they have higher concentrations of insulin-like growth factor I (IGF-I).

112 The receptor for insulin-like growth factor I (IGF-IR) controls normal an

113 le strength, and serum human growth hormone, insulin-like growth factor-I (IGF-1), IGF binding protei

114 Insulin and insulin-like growth factor-I (IGF-I) affect proliferatio

115 d basal and ligand-induced activation of the insulin-like growth factor-I (IGF-I) and ErbB3 receptor

116 perimental and clinical studies suggest that insulin-like growth factor-I (IGF-I) and IGF binding pro

117 r-promoting effects of obesity, signaling by insulin-like growth factor-I (IGF-I) and insulin has rec

118 rase (Pcmt1-/- mice) have alterations in the insulin-like growth factor-I (IGF-I) and insulin recepto

119 Insulin-like growth factor-I (IGF-I) and insulin-like gr

120 Insulin-like growth factor-I (IGF-I) and transforming gr

121 The growth hormone (GH)-insulin-like growth factor-I (IGF-I) axis regulates soma

122 GFBP)-1 influences fetal growth by modifying insulin-like growth factor-I (IGF-I) bioavailability.

123 Estradiol (E(2)) and insulin-like growth factor-I (IGF-I) can act independent

124 Here, we report that insulin-like growth factor-I (IGF-I) completely blocked

125 Growth hormone (GH) regulates insulin-like growth factor-I (IGF-I) gene expression thr

126 alysis was performed to examine the level of insulin-like growth factor-I (IGF-I) gene expression.

127 RNA expression of two splice variants of the insulin-like growth factor-I (IGF-I) gene, IGF-IEa and m

128 Circulating insulin-like growth factor-I (IGF-I) has been studied ex

129 Macrophage-derived insulin-like growth factor-I (IGF-I) has long been impli

130 Insulin-like growth factor-I (IGF-I) has significant str

131 tudies imply there is a significant role for insulin-like growth factor-I (IGF-I) in determining BMD.

132 Because recent studies have implicated insulin-like growth factor-I (IGF-I) in the pathogenesis

133 e present study, we investigated the role of insulin-like growth factor-I (IGF-I) in the regulation o

134 Growth hormone (GH) and insulin-like growth factor-I (IGF-I) increase intestinal

135 The ovarian hormone estradiol (E(2)) and insulin-like growth factor-I (IGF-I) interact in the CNS

136 Insulin-like growth factor-I (IGF-I) is a polypeptide ho

137 Insulin-like growth factor-I (IGF-I) is an essential gro

138 Insulin-like growth factor-I (IGF-I) is an important reg

139 among men in the top tertile of circulating insulin-like growth factor-I (IGF-I) levels [OR(per alle

140 olonged elevation of growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels, and vigorou

141 l and neuropsychological recovery, and serum insulin-like growth factor-I (IGF-I) may mediate this ef

142 Two muscle insulin-like growth factor-I (IGF-I) mRNA splice variant

143 for bone morphogenetic protein-2 (BMP-2) and insulin-like growth factor-I (IGF-I) on Osx expression a

144 othesis that shear stress interacts with the insulin-like growth factor-I (IGF-I) pathway to stimulat

145 onic treatment with erythropoietin (EPO) and insulin-like growth factor-I (IGF-I) protects against HI

146 Insulin-like growth factor-I (IGF-I) protects neurons of

147 Inhibitors of the insulin-like growth factor-I (IGF-I) receptor have been

148 There is evidence that the insulin-like growth factor-I (IGF-I) receptor is require

149 We demonstrate that decorin binds to the insulin-like growth factor-I (IGF-I) receptor on endothe

150 estigated the role of 14-3-3sigma protein in insulin-like growth factor-I (IGF-I) receptor signaling.

151 Insulin-like growth factor-I (IGF-I) receptors and insul

152 Insulin and insulin-like growth factor-I (IGF-I) receptors are highl

153 Insulin-like growth factor-I (IGF-I) regulates human int

154 FOXO4, an insulin/insulin-like growth factor-I (IGF-I) responsive transcri

155 Meanwhile, aberrant activation of the insulin-like growth factor-I (IGF-I) signaling has been

156 Substantial evidence implicates insulin-like growth factor-I (IGF-I) signaling in the de

157 ay be through constitutive activation of the insulin-like growth factor-I (IGF-I) signaling pathway,

158 s been shown to be an important regulator of insulin-like growth factor-I (IGF-I) signaling.

159 substrate 1 (IRS-1), a molecule transmitting insulin-like growth factor-I (IGF-I) signals through the

160 Insulin-like growth factor-I (IGF-I) stimulates vascular

161 Insulin-like growth factor-I (IGF-I) stimulates vascular

162 We have previously reported that insulin-like growth factor-I (IGF-I) supports growth and

163 d apoptosis in sarcoma cells is inhibited by insulin-like growth factor-I (IGF-I) through a signaling

164 that new synthesis of E2F-1 is required for insulin-like growth factor-I (IGF-I) to induce cyclin A

165 sion in PC-3 cells attenuated the ability of insulin-like growth factor-I (IGF-I) to induce phosphory

166 Diaphragm insulin-like growth factor-I (IGF-I) was increased in LV

167 tained in normal (5.6 mm) glucose respond to insulin-like growth factor-I (IGF-I) with increased prot

168 e anabolic actions of growth hormone (GH) is insulin-like growth factor-I (IGF-I), a 70-amino acid se

169 fects of growth hormone (GH) are mediated by insulin-like growth factor-I (IGF-I), a secreted peptide

170 rowth and tissue maintenance are mediated by insulin-like growth factor-I (IGF-I), a secreted protein

171 nt include reductions in insulin, estradiol, insulin-like growth factor-I (IGF-I), and free testoster

172 Epidermal growth factor (EGF), insulin-like growth factor-I (IGF-I), and heregulin-beta

173 ne, prolactin, sex hormone binding globulin, insulin-like growth factor-I (IGF-I), and IGF binding pr

174 dium increased after 8 to 16 hours in serum, insulin-like growth factor-I (IGF-I), epidermal growth f

175 Insulin-like growth factor-I (IGF-I), IGF-II, and insuli

176 ertal children to investigate the effects of insulin-like growth factor-I (IGF-I), insulin-like growt

177 wn 0, 10, 20, and 40 days postburn and serum insulin-like growth factor-I (IGF-I), insulin-like growt

178 rine regulators of bone-derived osteoblasts, insulin-like growth factor-I (IGF-I), is also present in

179 h muscle cells, exposed to hyperglycemia and insulin-like growth factor-I (IGF-I), SHPS-1 functions a

180 l cytokines such as interleukin-6 (IL-6) and insulin-like growth factor-I (IGF-I), which could protec

181 We investigated the hypotheses that (a) insulin-like growth factor-I (IGF-I)- and hepatocyte gro

182 Activation of the MAPK pathway mediates insulin-like growth factor-I (IGF-I)-dependent prolifera

183 In the total population, insulin-like growth factor-I (IGF-I)-enhanced cell cycle

184 retinoid receptor expression, and changes in insulin-like growth factor-I (IGF-I)-induced proliferati

185 azone and troglitazone) remarkably inhibited insulin-like growth factor-I (IGF-I)-promoted skin tumor

186 In Rh1 cells rapamycin inhibited insulin-like growth factor-I (IGF-I)-stimulated phosphor

187 g but can also be maintained with insulin or insulin-like growth factor-I (IGF-I).

188 esponse to epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I).

189 this process have been identified, including insulin-like growth factor-I (IGF-I).

190 The expression of two isoforms of insulin-like growth factor-I (IGF-I): mechano growth fac

191 rotective effects of a liver-type isoform of insulin-like growth factor-I (IGF-IEa) and its splice va

192 The insulin-like growth factors (insulin-like growth factor I [IGF-I] and IGF-II) exert i

193 s (expressing increased levels of the type 1 insulin-like growth factor I [IGF-I] receptor [IGF-IR])

194 t on circulating levels of glucose, insulin, insulin-like growth factor-I, IGF binding protein-3, lep

195 ion, there was about a 30% decrease in serum insulin-like growth factor I (IGF1), and while the serum

196 ulated actively by components of the insulin/insulin-like growth factor I (IGFI) pathway in laborator

197 of single-chain analogs (mini-proinsulin and insulin-like growth factor I) in which foreshortened con

198 Growth factors like insulin-like growth factor-I induce mTOR to prevent cell

199 1 also inhibited epidermal growth factor and insulin-like growth factor I-induced ERK and cell prolif

200 activity) but had little effect on basal or insulin-like growth factor I-induced proliferation.

201 Neither interleukin 6 nor insulin-like growth factor I inhibited CT-32615-induced

202 Insulin-like growth factor-I inhibits transforming growt

203 AR-/- mammary glands involves the defects of insulin-like growth factor I-insulin-like growth factor

204 The insulin-like growth factor I/insulin receptor substrate

205 factor/epidermal growth factor receptor and insulin-like growth factor-I/insulin-like growth factor-

206 individualising GH doses to normalize serum insulin-like growth factor-I level have shown a similar

207 GH secretion in health to maintain a similar insulin-like growth factor-I level to males.

208 7 significantly increased growth hormone and insulin-like growth factor I levels to those of healthy

209 Growth hormone and insulin-like growth factor I levels.

210 n tumor tissues and reduction of circulating insulin-like growth factor-I levels, suggesting that SPC

211 nd a 2-disulfide intermediate of long Arg(3) insulin-like growth factor-I (LR(3)IGF-I), which was the

212 may be induced by MSA via its modulation of insulin-like growth factor-I-mediated signal transductio

213 Previously we demonstrated that insulin-like growth factor-I mediates the sustained phos

214 promoted significant increases in intestinal insulin-like growth factor-I mRNA but did not affect pla

215 ely correlated with the expression levels of insulin-like growth factor-I mRNA, suggesting a feedback

216 Transforming growth factor-beta1 and insulin-like growth factor-I offer mechanoprotection and

217 We have shown previously that insulin-like growth factor-I or lens epithelium-derived

218 ir defect can be complemented with exogenous insulin-like growth factors I or II.

219 ich was stimulated by growth factors (serum, insulin-like growth factor I, or fibroblast growth facto

220 experienced a 10% greater increase in serum insulin-like growth factor I (P < 0.05) and a 16% greate

221 mini nutritional assessment (P = 0.003), and insulin-like growth factor I (P = 0.002), and lowered C-

222 human epidermal growth factor, insulin, and insulin-like growth factor I, particularly at the parasi

223 The impaired insulin-like growth factor I pathway in AIB1(-/-)-ras ma

224 g pathway components, and modulations of the insulin-like growth factor I pathway.

225 and increased signaling through the insulin/insulin-like growth factor-I/phosphatidylinositol 3-kina

226 Stimulation of PI3-kinase/Akt by insulin-like growth factor I potentiates Gli activation

227 Insulin-like growth factor I receptor (IGF-1R) signaling

228 has been implicated in negatively regulating insulin-like growth factor I receptor (IGF-IR) activity.

229 eloped which binds specifically to the human insulin-like growth factor I receptor (IGF-IR) and inhib

230 Insulin-like growth factor I receptor (IGF-IR) and its l

231 Grb10 is an interacting partner of the insulin-like growth factor I receptor (IGF-IR) and the i

232 The insulin-like growth factor I receptor (IGF-IR) and the i

233 Alterations in insulin-like growth factor I receptor (IGF-IR) have been

234 Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new

235 The insulin-like growth factor I receptor (IGF-IR) is a tran

236 The insulin-like growth factor I receptor (IGF-IR) is overex

237 ostulated that mutations in the gene for the insulin-like growth factor I receptor (IGF-IR) might und

238 d receptor clustering and is associated with insulin-like growth factor I receptor (IGF-IR), a recept

239 a cascade of events, including activation of insulin-like growth factor I receptor (IGF-IR), phosphat

240 onal immunoglobulin G1 antibody that targets insulin-like growth factor I receptor (IGF-IR).

241 n the next promising therapeutic target, the insulin-like growth factor I receptor (IGF-IR).

242 The tyrosine kinase activity of insulin-like growth factor I receptor (IGF1R) is under t

243 ved growth factor receptor beta (Pdgfrb) and insulin-like growth factor I receptor (Igf1r) on T-ALL c

244 The insulin-like growth factor I receptor (IGFIR) and HER2 d

245 increased copy number at chromosome 15q26.3 insulin-like growth factor I receptor (IGFIR) and tumor

246 sensitivity to small molecule inhibitors of insulin-like growth factor I receptor and c-Met.

247 were enriched in the "CTNNB1" class, whereas insulin-like growth factor I receptor and RPS6 phosphory

248 Inhibition of AKT, TORC1/2, or insulin-like growth factor I receptor blocked AZD6244-in

249 deprivation affects AKT activity by reducing insulin-like growth factor I receptor sensitivity to gro

250 orming growth factor beta, interferon gamma, insulin-like growth factor I receptor, activating transc

251 2, rearranged during transfection (RET), and insulin-like growth factor I receptor.

252 Here, we report that insulin-like growth factor-I receptor (IGF-IR) activatio

253 Epidermal growth factor receptor (EGFR) and insulin-like growth factor-I receptor (IGF-IR) can coope

254 A role for hyperinsulinemia and increased insulin-like growth factor-I receptor (IGF-IR) expressio

255 Insulin-like growth factor-I receptor (IGF-IR) hyperstim

256 Overexpression and enhanced activity of insulin-like growth factor-I receptor (IGF-IR) in divers

257 ecorin core protein can bind to and activate insulin-like growth factor-I receptor (IGF-IR) in endoth

258 he growth factor receptors erbB2, erbB3, and insulin-like growth factor-I receptor (IGF-IR) in trastu

259 Knockdown of InsR and/or insulin-like growth factor-I receptor (IGF-IR) inhibited

260 Insulin-like growth factor-I receptor (IGF-IR) is a prot

261 Insulin-like growth factor-I receptor (IGF-IR) is freque

262 Signaling through the insulin-like growth factor-I receptor (IGF-IR) is implic

263 The insulin-like growth factor-I receptor (IGF-IR) monoclona

264 shown by several groups as well as ours that insulin-like growth factor-I receptor (IGF-IR) overexpre

265 sion resulted in a 44-60% reduction in total insulin-like growth factor-I receptor (IGF-IR) protein l

266 oding a dominant-negative, kinase-dead human insulin-like growth factor-I receptor (IGF-IR) that is e

267 fibronectin, a major ECM component, engages insulin-like growth factor-I receptor (IGF-IR) to inhibi

268 ent study, we show that HER-2 interacts with insulin-like growth factor-I receptor (IGF-IR) uniquely

269 Activation of the insulin-like growth factor-I receptor (IGF-IR) was recen

270 ammalian target of rapamycin (mTOR) pathway, insulin-like growth factor-I receptor (IGF-IR), and mito

271 Agents targeting insulin-like growth factor-I receptor (IGF-IR), includin

272 we demonstrate that a specific inhibitor of insulin-like growth factor-I receptor (IGF-IR), NVP-AEW5

273 t epidermal growth factor receptor (EGFR) or insulin-like growth factor-I receptor (IGFR).

274 Because the insulin-like growth factor-I receptor has been implicate

275 Insulin-like growth factor-I receptor targeted monoclona

276 that IGF-II-initiated signaling through the insulin-like growth factor-I receptor targets transcript

277 responsible for continued activation of the insulin-like growth factor-I receptor, suggesting a role

278 lved in breast carcinogenesis via regulating insulin-like growth factor-I receptor-dependent signalin

279 tus, including MDA-MB-231, BT474, SKBR3, and insulin-like growth factor-I receptor-overexpressing SKB

280 major signaling molecule for the insulin and insulin-like growth factor I receptors, which transduces

281 naling molecule activated by the insulin and insulin-like growth factor I receptors.

282 tor I administration, the use of recombinant insulin-like growth factor I should be limited to those

283 elevated level of Klotho and suppression of insulin-like growth factor I signaling, which may be the

284 The suppression of these components for insulin-like growth factor-I signaling might be partiall

285 tudy, we investigated the mechanisms whereby insulin-like growth factor-I signaling, through the insu

286 Insulin-like growth factor-I stimulates differentiation

287 on than PTEN-expressing cells in response to insulin-like growth factor I stimulation, we determined

288 We showed that insulin-like growth factor-I stimulation induced loss of

289 T-20/IRS-1 cells, is replaced by IRS-1 after insulin-like growth factor-I stimulation.

290 pathways (e.g., hypoxia-inducible factor and insulin-like growth factor-I) that reflect the intrinsic

291 e delivery of administered recombinant human insulin-like growth factor I to other tissues, including

292 sk profile, the limited ability of endocrine insulin-like growth factor I to restore normal growth, a

293 and p42/44 mitogen-activated protein kinase; insulin-like growth factor-I-triggered Akt phosphorylati

294 bolic variables, including glucose, insulin, insulin-like growth factor I, triglycerides, cholesterol

295 ly, stimulation of ERK1 and ERK2 activity by insulin-like growth factor I was reduced when IQGAP1 lev

296 ctors, brain-derived neurotrophic factor and insulin-like growth factor I, were examined in the rat m

297 om milk, can elevate serum concentrations of insulin-like growth factor I, which has an unknown relat

298 ogenic potential, and growth factors such as insulin-like growth factor I, which have been shown to p

299 Neither interleukin-6 nor insulin-like growth factor-I, which both induce multiple

300 rinary deoxypyridinoline and increased serum insulin-like growth factor I without affecting parathyro